CR20170469A - Proteínas de fusión - Google Patents

Proteínas de fusión

Info

Publication number
CR20170469A
CR20170469A CR20170469A CR20170469A CR20170469A CR 20170469 A CR20170469 A CR 20170469A CR 20170469 A CR20170469 A CR 20170469A CR 20170469 A CR20170469 A CR 20170469A CR 20170469 A CR20170469 A CR 20170469A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
present
diabetes
useful
treatment
Prior art date
Application number
CR20170469A
Other languages
English (en)
Spanish (es)
Inventor
Jhon Michael Beals
Jonathan Wesley Day
Gregory Alan Lazar
Craig Duane Dickinson
Andrew Ihor Korytko
David Bruce Baldwin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170469(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20170469A publication Critical patent/CR20170469A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
CR20170469A 2015-05-07 2016-04-28 Proteínas de fusión CR20170469A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07
PCT/US2016/029807 WO2016178905A1 (en) 2015-05-07 2016-04-28 Fusion proteins

Publications (1)

Publication Number Publication Date
CR20170469A true CR20170469A (es) 2017-11-14

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170469A CR20170469A (es) 2015-05-07 2016-04-28 Proteínas de fusión

Country Status (40)

Country Link
US (5) US9855318B2 (enExample)
EP (1) EP3292141B1 (enExample)
JP (1) JP6591562B2 (enExample)
KR (1) KR102059736B1 (enExample)
CN (1) CN107531806B (enExample)
AR (1) AR105616A1 (enExample)
AU (1) AU2016257659B2 (enExample)
CA (1) CA2981102A1 (enExample)
CL (1) CL2017002761A1 (enExample)
CO (1) CO2017011301A2 (enExample)
CR (1) CR20170469A (enExample)
CY (1) CY1122929T1 (enExample)
DK (1) DK3292141T3 (enExample)
DO (1) DOP2017000258A (enExample)
EA (1) EA039770B1 (enExample)
EC (1) ECSP17073650A (enExample)
ES (1) ES2799099T3 (enExample)
HR (1) HRP20200503T1 (enExample)
IL (1) IL254965B (enExample)
JO (1) JO3658B1 (enExample)
LT (1) LT3292141T (enExample)
MA (1) MA42037B1 (enExample)
MD (1) MD3292141T2 (enExample)
ME (1) ME03709B (enExample)
MX (1) MX388594B (enExample)
MY (1) MY183025A (enExample)
NZ (1) NZ736470A (enExample)
PE (1) PE20180507A1 (enExample)
PH (1) PH12017502025B1 (enExample)
PL (1) PL3292141T3 (enExample)
PT (1) PT3292141T (enExample)
RS (1) RS60044B1 (enExample)
SG (1) SG11201708194WA (enExample)
SI (1) SI3292141T1 (enExample)
SV (1) SV2017005548A (enExample)
TN (1) TN2018000059A1 (enExample)
TW (1) TWI656132B (enExample)
UA (1) UA122146C2 (enExample)
WO (1) WO2016178905A1 (enExample)
ZA (1) ZA201706334B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー/エス 極性の組換え延長部を有するインスリン
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3798001A1 (en) 2016-07-27 2021-03-31 Hewlett-Packard Development Company, L.P. Horizontal interface for fluid supply cartridge having digital fluid level sensor
EP3939605A1 (en) * 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
MA49339A (fr) * 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
ES2932861T3 (es) * 2018-01-26 2023-01-27 Hoffmann La Roche Composiciones de IL-22 Fc y procedimientos de uso
JP2021528052A (ja) 2018-06-25 2021-10-21 ユニバーシティ オブ ワシントンUniversity of Washington 強力で選択的なインターロイキン模倣体のデノボ設計
US11267862B2 (en) * 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
BR112020026777A2 (pt) 2018-06-29 2021-03-30 Akston Biosciences Corporation Proteínas de fusão, composição farmacêutica, método para reduzir o nível de glicose, célula e cdna
CN112839681A (zh) 2018-10-10 2021-05-25 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物及其医学用途
CN120040576A (zh) 2018-11-20 2025-05-27 华盛顿大学 分拆白介素模拟物和它们的用途
JP7728176B2 (ja) * 2019-03-15 2025-08-22 イーライ リリー アンド カンパニー 保存製剤
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TW202434620A (zh) * 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
DK4073098T5 (da) 2019-12-19 2024-07-22 Akston Biosciences Corp Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US20230340071A1 (en) 2020-03-16 2023-10-26 Neoleukin Therapeutics, Inc. Interleukin-2 Receptor Beta (IL-2RB) Binding Polypeptides
CA3173628A1 (en) 2020-04-07 2021-10-14 Thomas Linsky De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN113968911B (zh) * 2020-07-24 2023-10-10 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
EP4240407A1 (en) * 2020-11-06 2023-09-13 Amgen Inc. Antigen binding domain with reduced clipping rate
AU2021401635A1 (en) * 2020-12-14 2023-06-22 Eli Lilly And Company Methods of treating diabetes
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
AR127619A1 (es) * 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc
WO2023174370A1 (zh) * 2022-03-16 2023-09-21 北京拓界生物医药科技有限公司 人胰岛素类似物、其融合蛋白及医药用途
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체
CN119403824A (zh) 2022-06-23 2025-02-07 赛诺菲 单链胰岛素及其Fc缀合物
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白
WO2024229093A1 (en) 2023-05-03 2024-11-07 Eli Lilly And Company Methods and systems for managing diabetes
WO2025059010A1 (en) 2023-09-11 2025-03-20 Eli Lilly And Company Methods and systems for managing diabetes
WO2025061146A1 (zh) * 2023-09-20 2025-03-27 上海迈晋生物医药科技有限公司 一种人胰岛素类似物融合蛋白的药物组合物及其医药用途
WO2025080923A1 (en) 2023-10-13 2025-04-17 Eli Lilly And Company Insulin-fc fusion proteins
US12454565B2 (en) 2024-03-21 2025-10-28 Akston Biosciences Corporation PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1996034882A1 (en) 1995-05-05 1996-11-07 Eli Lilly And Company Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2369839A1 (en) 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US7448763B2 (en) 2003-10-02 2008-11-11 Carl Zeiss Smt Ag Optical subassembly and projection objective in semiconductor lithography
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
JP2009527526A (ja) 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー/エス 単鎖インスリンのアナログとその製薬的製剤
WO2007104737A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
CA2687377C (en) * 2007-05-30 2013-05-14 Genexine Co., Ltd. Immunoglobulin fusion proteins
EP2175834B8 (en) 2007-07-10 2012-08-22 Eli Lilly And Company Glp-1-fc fusion protein formulation
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
ES2611007T3 (es) * 2008-03-18 2017-05-04 Novo Nordisk A/S Análogos de insulina acilada, estabilizados frente a proteasas
KR20110021758A (ko) 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
US9636420B2 (en) 2008-07-23 2017-05-02 Hanmi Science Co., Ltd. Polypeptide complex comprising non-peptidyl polymer having three functional ends
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
AU2012214419B2 (en) 2011-02-09 2015-12-24 Glaxosmithkline Llc Lyophilized formulations
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
EP2869830B1 (en) 2012-07-09 2016-10-12 Novo Nordisk A/S Novel use of insulin derivatives
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリンアナローグダイマー
WO2014071405A2 (en) 2012-11-05 2014-05-08 Case Western Reserve University Long-acting single-chain insulin analogues
CA2899418C (en) 2013-02-26 2022-05-03 Hanmi Pharm. Co., Ltd. Site-specific insulin conjugate
AU2014236451B2 (en) * 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
EP3055325B1 (en) 2013-10-07 2018-01-03 Novo Nordisk A/S Novel derivative of an insulin analogue
MA46146A1 (fr) 2014-01-20 2020-12-31 Hanmi Pharm Ind Co Ltd Insuline a action prolongée et utilisation associée
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
CN107108716A (zh) 2014-10-06 2017-08-29 卡斯西部储备大学 双相性单链胰岛素类似物
ES2946247T3 (es) 2014-11-21 2023-07-14 Merck Sharp & Dohme Llc Agonistas parciales del receptor de insulina
EP3260139A4 (en) 2015-02-17 2018-09-05 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue complex
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
MX2017014284A (es) 2018-03-23
EP3292141B1 (en) 2020-02-12
US12059452B2 (en) 2024-08-13
US20220211818A1 (en) 2022-07-07
ES2799099T3 (es) 2020-12-14
UA122146C2 (uk) 2020-09-25
US20200390865A1 (en) 2020-12-17
JP2018515088A (ja) 2018-06-14
JO3658B1 (ar) 2020-08-27
EA201792199A1 (ru) 2018-03-30
CO2017011301A2 (es) 2018-03-20
LT3292141T (lt) 2020-03-25
IL254965A0 (en) 2017-12-31
CL2017002761A1 (es) 2018-05-18
EP3292141A1 (en) 2018-03-14
US20180177851A1 (en) 2018-06-28
ZA201706334B (en) 2020-01-29
PH12017502025A1 (en) 2018-04-02
MD3292141T2 (ro) 2020-07-31
AU2016257659A1 (en) 2017-10-12
JP6591562B2 (ja) 2019-10-16
CN107531806B (zh) 2022-06-07
EA039770B1 (ru) 2022-03-11
SV2017005548A (es) 2018-04-24
US9855318B2 (en) 2018-01-02
HRP20200503T1 (hr) 2020-06-26
US20250032588A1 (en) 2025-01-30
US20160324932A1 (en) 2016-11-10
ME03709B (me) 2021-01-20
SI3292141T1 (sl) 2020-04-30
TN2018000059A1 (en) 2019-07-08
MY183025A (en) 2021-02-07
PT3292141T (pt) 2020-04-22
TWI656132B (zh) 2019-04-11
TW201712029A (zh) 2017-04-01
IL254965B (en) 2021-03-25
BR112017020502A2 (pt) 2018-07-03
KR20170134614A (ko) 2017-12-06
CN107531806A (zh) 2018-01-02
WO2016178905A1 (en) 2016-11-10
NZ736470A (en) 2019-04-26
MX388594B (es) 2025-03-20
AU2016257659B2 (en) 2018-08-09
DK3292141T3 (da) 2020-04-20
US11253574B2 (en) 2022-02-22
MA42037B1 (fr) 2020-03-31
PE20180507A1 (es) 2018-03-09
HK1244019A1 (en) 2018-07-27
PL3292141T3 (pl) 2020-06-29
AR105616A1 (es) 2017-10-25
DOP2017000258A (es) 2017-12-31
KR102059736B1 (ko) 2019-12-26
SG11201708194WA (en) 2017-11-29
US10709766B2 (en) 2020-07-14
RS60044B1 (sr) 2020-04-30
ECSP17073650A (es) 2018-02-28
CY1122929T1 (el) 2021-10-29
CA2981102A1 (en) 2016-11-10
PH12017502025B1 (en) 2018-04-02

Similar Documents

Publication Publication Date Title
ECSP17073650A (es) Proteínas de fusión
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EA201790063A1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
CL2018002687A1 (es) Proteínas de unión y métodos de uso de las mismas
AR106144A1 (es) Un conjugado de proteína que comprende polipéptidos fisiológicos y una región fc inmunoglobulina
CR20180378A (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
EA201790213A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
UY36370A (es) Polipéptidos fgf-21 modificados y sus usos
PL3765489T3 (pl) Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
IL276616A (en) Dosage for treatment with IL-22 Fc fusion proteins
CR20150477A (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
BR112021011595A2 (pt) Proteína biespecífica
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
AR099080A1 (es) Variantes de región fc con propiedades de unión a fcrn (receptor fc neonatal) modificadas y de unión a proteína a mantenidas
TH177202A (th) โพลีเปปไทด์ IL-22 และฟิวชันโปรตีน IL-22 Fc และวิธีการใช้
AR090915A1 (es) Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg